Core Viewpoint - The controversy surrounding the skincare brand Kefu Mei, owned by Juzhi Biotechnology, has raised significant concerns about the authenticity of its flagship product, the recombinant collagen essence, which was alleged to contain only 0.0177% collagen, contradicting regulatory standards that require non-trace ingredients to exceed 0.1% [1][2][3] Company Summary - Juzhi Biotechnology, established in 2000, is a leading player in the recombinant collagen market in China, with a revenue growth from 900 million yuan in 2019 to 5.5 billion yuan in 2024, marking a more than fivefold increase [8] - The company reported a revenue of 5.539 billion yuan in 2024, a year-on-year increase of 57.2%, and a net profit of 2.062 billion yuan, up 42.1% [8] - Kefu Mei, the core brand of Juzhi Biotechnology, generated 4.54 billion yuan in revenue in 2024, reflecting a significant growth of 62.9% [9] Industry Summary - The recombinant collagen market in China was valued at 10.8 billion yuan in 2021 and is projected to surge to 219.38 billion yuan by 2030, with a compound annual growth rate of 44.93% [8] - The absence of industry standards for the collagen content in cosmetics has led to regulatory ambiguities, as highlighted by the ongoing controversy [7] - The recent scrutiny of Juzhi Biotechnology's products comes at a time when recombinant collagen is gaining popularity in the cosmetic industry, potentially replacing hyaluronic acid as a preferred ingredient [9]
重组胶原检测不到？巨子生物又陷舆论风波，股价两日跌去10%